https://biotechmorning.com/news/evommune-mrgprx2-eczema-drug-second-phase-2-failure Biotech Morning en 2026-09-10T14:18:52.154Z The Itch Drug That Couldn't Scratch the Surface https://biotechmorning.com/news/novartis-alteogen-subcutaneous-delivery-deal Biotech Morning en 2026-09-10T14:18:05.170Z Novartis Just Bet $3.2 Billion on Killing the IV Drip https://biotechmorning.com/news/first-ai-designed-drug-phase-3-trial Biotech Morning en 2026-09-10T14:17:17.229Z The First AI-Designed Drug Just Reached the Final Boss of Clinical Trials https://biotechmorning.com/news/bayer-sevabertinib-her2-lung-cancer-approval Biotech Morning en 2026-09-10T14:16:33.127Z Bayer Just Crashed the HER2 Lung Cancer Party https://biotechmorning.com/news/samsung-biologics-polypeptide-takeover-peptide-cdmo Biotech Morning en 2026-09-10T14:15:47.110Z Samsung Biologics Just Bet $1.8 Billion on a Single Molecule https://biotechmorning.com/news/mogad-first-approved-treatment-roche-enspryng Biotech Morning en 2026-09-10T14:15:04.709Z The Disease With Zero Approved Treatments Might Finally Get One https://biotechmorning.com/news/roche-simcere-sim0660-preclinical-deal Biotech Morning en 2026-09-10T14:14:18.952Z Roche Just Paid $1.53 Billion for a Drug That's Never Been in a Human https://biotechmorning.com/news/arpa-h-ai-heart-failure-advocate Biotech Morning en 2026-09-10T14:13:28.896Z The Government Wants an AI Doctor for Your Heart https://biotechmorning.com/news/lasker-award-orexin-sleep-scientists-nobel-track Biotech Morning en 2026-09-10T14:12:42.650Z The Sleep Scientists Who Might Be on a Fast Track to Stockholm https://biotechmorning.com/news/novartis-del-desiran-rna-drug-phase-3-failure Biotech Morning en 2026-09-10T14:11:59.487Z Novartis Spent $12 Billion on an RNA Drug. It Just Flopped. https://biotechmorning.com/news/novartis-tourmaline-bio-il6-cardiovascular-deal Biotech Morning en 2026-09-10T14:11:14.954Z Novartis Just Paid $1.4 Billion to Fight Heart Attacks With Inflammation https://biotechmorning.com/news/bbo-8520-kras-g12c-resistant-lung-cancer Biotech Morning en 2026-09-09T14:18:03.247Z The Lung Cancer Drug That Works After Everything Else Stops https://biotechmorning.com/news/pharvaris-oral-hae-pill-phase-3-win Biotech Morning en 2026-09-09T14:17:15.203Z The Pill That Wants to Replace Your Needle https://biotechmorning.com/news/intellia-crispr-lonvo-z-fda-priority-review Biotech Morning en 2026-09-09T14:16:29.920Z One Shot to Rewrite Your DNA: The CRISPR Therapy Knocking on the FDA's Door https://biotechmorning.com/news/astrazeneca-tozorakimab-copd-biologic Biotech Morning en 2026-09-09T14:15:39.719Z AstraZeneca Just Crashed the Inhaler Party With a $5B Biologic https://biotechmorning.com/news/novartis-del-desiran-harbor-trial-failure Biotech Morning en 2026-09-09T14:14:54.862Z Novartis Bet $12 Billion on This Drug. It Just Flopped. https://biotechmorning.com/news/ox40-agonist-inhibrx-comeback Biotech Morning en 2026-09-09T14:14:08.322Z The Immunotherapy Target Everyone Gave Up On Just Came Back to Life https://biotechmorning.com/news/roivant-mosliciguat-pulmonary-hypertension-10-billion Biotech Morning en 2026-09-09T14:13:22.517Z Roivant's Lung Drug Just Posted Data That Has Wall Street Buzzing https://biotechmorning.com/news/blood-test-catches-breast-cancer-fighting-back Biotech Morning en 2026-09-09T14:12:37.870Z The Blood Test That Catches Breast Cancer Fighting Back https://biotechmorning.com/news/sclc-imdelltra-imfinzi-survival-win Biotech Morning en 2026-09-09T14:11:48.903Z The Cancer That Keeps Winning Just Lost a Round